Clinical Reviews in Bone and Mineral Metabolism

, Volume 4, Issue 4, pp 277–290

The use of teriparatide and PTH(1–84) for the treatment of osteoporosis

Article
  • 62 Downloads

Abstract

Different therapeutic formulations of parathyroid hormone (PTH) have been studied for the treatment of osteoporosis: synthetic teriparatide [hPTH(1–34)], reconstituted from lysophilized powder; recombinant human teriparatide [rhPTH(1–34)], which has been commercially available since 2002; and PTH(1–84), which is under review by the US Food and Drug Administration (FDA). Teriparatide has demonstrated vertebral and nonvertebral vertebral antifracture efficacy, increases in BMD and biochemical markers of bone turnover, the cornerstones of judging success with an osteoporosis agent. PTH (1–84) may be an alternative consideration for the treatment of both the prevention of the first vertebral fracture as well as the reduction in future vertebral fracture risk in postmenopausal women with existing vertebral fractures. It remains to be seen if there are therapeutic differences between the already approved teriparatide and yet-to-be-approved PTH(1–84).

Key Words

Osteoporosis teriparatide PTH(1–34) PTH (1–84) fracture bone mineral density biochemical markers of bone turnover 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Black DM, Cummings SR, Karpf DB et al. 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541.PubMedCrossRefGoogle Scholar
  2. 2.
    Chesnut CH, Silverman S, Andriano K et al. 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 109:267–276.PubMedCrossRefGoogle Scholar
  3. 3.
    Cummings SR, Black DM, Thompson DE, et al. 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures JAMA 280: 2077–2082.PubMedCrossRefGoogle Scholar
  4. 4.
    Ettinger B, Black DM, Mitlak BH et al. 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282:637–645.PubMedCrossRefGoogle Scholar
  5. 5.
    Harris ST, Watts NB, Genant HK et al. 1999 Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. JAMA 282:1344–1352.PubMedCrossRefGoogle Scholar
  6. 6.
    Reginster JY, Minne HW, Sorensen OH et al. 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83–91.PubMedCrossRefGoogle Scholar
  7. 7.
    Wasnich RD, 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:1–6.CrossRefGoogle Scholar
  8. 8.
    Cummings SR, Karpf DB, Harris F et al. 2002 Improvement in spine bone density and reduction in risk of vertebral fracture during treatment with antiresorptive drugs. Am J Med 112:281–289.PubMedCrossRefGoogle Scholar
  9. 9.
    Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J. Bone Miner Res 17:1–10.PubMedCrossRefGoogle Scholar
  10. 10.
    Sorenson O, Kaufman JM, Wenderoth D, Chines A. 2003 Sustained effect of risedronate: a 7-year study in postmenopausal women, 9th Annual Meeting of the International Society for Clinical Densitometry. Abstract 43 K.Google Scholar
  11. 11.
    Miller PD, 2005 Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteo Rep 3:103–110.Google Scholar
  12. 12.
    Strewler GJ, 2001 Physiologic actions of PTH and PTHrP: I. Skeletal actions. In: Bilezikian JP, Marcus R, Levine MA (eds) The Parathyroids: Basic and Clinical Concepts. Academic New York, pp. 213–226.Google Scholar
  13. 13.
    Bringhurst FR, 2001 Physiologic actions of PTH and PTHRP: II. Renal actions In: Bilezikian JP, Marcus R, Levine MA (eds) The Parathyroids: Basic and Clinical Concepts. Academic, New York, pp. 227–244.Google Scholar
  14. 14.
    Clemens TL, Broadus AE. 2001 Physiologic actions of PTH and PTHrP: IV. Vascular, cardiovascular, and neurologic actions. In: Bilezikian JP, Marcus R, Levine MA (eds) The Parathyroids: Basic and Clinical Concepts. Academic, New York, pp. 261–274.Google Scholar
  15. 15.
    Wysolmerski JJ, Stewart AF, Martin JT, 2001 Physiologic actions of PTH and PTHrP: V Epidermal, mammary, reproductive, and pancreatic tissues. In: Bilezikian JP, Marcus R, Levine MA (eds) The Parathyroids: Basic and Clinical Concepts. Academic New York, pp. 275–291.Google Scholar
  16. 16.
    Kronenberg HM, Binghurst FR, Segre GV, Potts JT, 2001 Parathyroid hormone biosynthesis and metabolism In: Bilezikian JP, Marcus R, Levine MA (eds) The Parathyroids: Basic and Clinical Concepts. Academic New York, pp. 17–30.Google Scholar
  17. 17.
    Miller PD, Bilezikian JP, Deal C, Harris ST, 2004 Clinical use of teriparatide in the real world: initial insights. Endocr Prac 10:139–148.Google Scholar
  18. 18.
    Hodsman AB, Bauer DC, Dempster DW, et al. 2005 Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688–703.PubMedCrossRefGoogle Scholar
  19. 19.
    Lindsay R, Nieves J, Formica C et al. 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550–555.PubMedCrossRefGoogle Scholar
  20. 20.
    Hodsman AB, Fraher LJ, Watson PH et al. 1997 A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 82:620–628.PubMedCrossRefGoogle Scholar
  21. 21.
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini A, Arnaud CD, 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 102:1627–1633.PubMedGoogle Scholar
  22. 22.
    Roe EB, Sanchez SD, del Puerto GA, Pierini E, Cann CE, Arnaud CD. 1999 Parathyroid hormonel 1–34 [hPTH(1–34)] and estrogen produce dramatic bone density increases in postmenopausal osteoporosis—results from a placebo-controlled randomized trial. J Bone Miner Res 14(Suppl 1): S137.Google Scholar
  23. 23.
    Cosman F, Nieves J, Woelfert L et al. 2001. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16: 925–931.PubMedCrossRefGoogle Scholar
  24. 24.
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. 2000 Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 15: 944–951PubMedCrossRefGoogle Scholar
  25. 24a.
    Wagman RB, Marcus R, Mutlak, BH. 2005. Treatment with parathyroid hormone. In: Drug Therapy for Osteoporosis, (M. Kleerekoper, ed.) Taylor & Francis, New York, pp. 91–112Google Scholar
  26. 25.
    Neer RM, Arnaud CD, Zanchetta JR et al. 2001 Effect of density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441.PubMedCrossRefGoogle Scholar
  27. 26.
    Vahle JL, Sato M, Long GG et al. 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Path 30:312–321.CrossRefGoogle Scholar
  28. 27.
    Vahle JL, Long GG, Ma YL, Sato M. 2004 Bone neoplasms in F344 rats given teriparatide [rhPTH (1–34)] are dependent on duration of treatment and dose. Toxicol Path 32: 426–438.CrossRefGoogle Scholar
  29. 28.
    Pohl, G.; Wang, J, Scheele, WH. 2003 Effect of duration of teriparatide therapy on nonvertebral fracture risk. Arthritis Rheum 48(Suppl 9):S234.Google Scholar
  30. 29.
    Lindsay R, Scheele WH, Neer R et al. 2004 Sustained vertebral fracture risk reduction after withdrawal of teriparatide [recombinant human parathyroid hormone (1–34)] in postmenopausal women with osteoporosis. Arch Intern Med 164:2024–2030.PubMedCrossRefGoogle Scholar
  31. 30.
    Prince RL, Sipos AA, Hossain A et al. 2005 Sustained non-vertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20: 1507–1513.PubMedCrossRefGoogle Scholar
  32. 31.
    Greenspan SL, Bone HG, Macciott TB et al. 2005 Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH (1–84): results from the TOP study. J Bone Miner Res 20(Suppl 1):S56Google Scholar
  33. 32.
    Hui SL, Slemenda CW, Johnston CC Jr. 1988 Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:1804–1809.PubMedCrossRefGoogle Scholar
  34. 33.
    Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B, 2001 Ten year probabilities of osteoporosis fracture according to BMD and diagnostic thresholds. Osteopor Int 12:989–995.CrossRefGoogle Scholar
  35. 34.
    FORTEO product labeling. Eli Lilly and Company, 2002, 2004.Google Scholar
  36. 35.
    Orwoll ES, Scheele WH, Paul S et al. 2003. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17.PubMedCrossRefGoogle Scholar
  37. 36.
    Kurland ES, Cosman F, McMahan DJ, Rosen CJ, Lindsay R, Bilezikian JP, 2000. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85: 3069–3076.PubMedCrossRefGoogle Scholar
  38. 37.
    McClung MR, San Martin J, Miller PD et al. 2005 Opposite bone remodelling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165: 1762–1768.PubMedCrossRefGoogle Scholar
  39. 38.
    Chen P, Satterwhite JH, Licata AA et al. 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Mineral Res 20: 962–970.CrossRefGoogle Scholar
  40. 39.
    Chen P, Miller PD, Delmas PD, Misurski DA, Krege JK. 2005 Change in lumbar spine (BMD) and vertebral fracture risk reduction in teriparatide-treated women with osteoporosis. J Bone Miner Res postmenopausal: 1985–1990.Google Scholar
  41. 40.
    Deal C, Omizo M, Schwartz EN et al. 2005. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results form a 6-month double blind placebo-controlled trial. J Bone Miner Res 20:905–911.CrossRefGoogle Scholar
  42. 41.
    Rittmaster RS, Bolognese M, Ettinger MP et al. 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129–2134.PubMedCrossRefGoogle Scholar
  43. 42.
    Black DM, Greenspan SL, Ensrud KE et al. 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215.PubMedCrossRefGoogle Scholar
  44. 43.
    Black DM, Bilezikian JP, Ensrud KE et al. 2005 One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 353:555–565.PubMedCrossRefGoogle Scholar
  45. 44.
    Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. 2004 The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1–34)]. Osteoporos Int 15:992–997.PubMedCrossRefGoogle Scholar
  46. 45.
    Krege J, Heathman M, Reginster J, Satterwhite J, 2003 Increases in serum-terminal propertide of type I collagen with teriparatide treatment predict increases in lumbar spine bone density. Program and Abstracts The Endocrine Society's 85th Annual Meetings, Philadelphia, PA, USA, June 19–22, 2003.Google Scholar
  47. 46.
    Ettinger B, San Martin J, Crans G, Imre Pavo. 2004 Response of markers of bone turnover and bone density to teriparatide in postmenopausal women previously treated with an antiresorptive drug. J Bone Miner Res 19: 745–751.PubMedCrossRefGoogle Scholar
  48. 47.
    Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. 2005 Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566–575.PubMedCrossRefGoogle Scholar
  49. 48.
    Delmas PD, Licata AA, Crans GG et al. 2004 Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. J Bone Miner Res 19(Suppl 1): S44.Google Scholar
  50. 49.
    Dempster DW, Cosman F, Kurland AS et al. 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16: 1846–1853.PubMedCrossRefGoogle Scholar
  51. 50.
    Jiang Y, Zhao J, Mitlak BH, Wang O, Genant HK, Eriksen EF. 2003 Recombinant Human Parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941.PubMedCrossRefGoogle Scholar
  52. 51.
    Arlot M, Meunier PJ, Boivin G et al. 2005 Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244–1253.PubMedCrossRefGoogle Scholar
  53. 52.
    Recker RR, Bare SP, Miller MA, Newman MK, Fox J. 2004 Treatment of osteoporotic women with parathyroid hormone 1–84 for 18 months improves cancellous bone formation and structure: a bone biopsy study. J Bone Miner Res (1 Suppl):S97.Google Scholar
  54. 53.
    Dempster DW, Moreau IA, Varela A et al. 2005 Treatment of postmenopausal osteoporotic women with parathyroid hormone 1–84 for 18 months improves trabecular bone architecture: a study of iliac crest biopsies using microcomputer tomography. J. Bone Miner Res (1 Suppl):S98.Google Scholar
  55. 54.
    Wilker CE, Jolette J, Smith SY et al. 2004 A No observable carcinogenic effect dose level identified in Fischer 344 rats following daily treatment with PTH (1–84) for 2 years: role of the c-terminal PTH receptor? J Bone Miner Res 19(Suppl 1):S98.Google Scholar
  56. 55.
    Tashjian AH, Chabner BA. 2002 Commentary on clinical safety of recombinant human parathyroid hormone 1–34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 17:1151–1161.PubMedCrossRefGoogle Scholar
  57. 56.
    Tashijan AH, Gagel RF. 2005 Teriparatide (human parathyroid hormone 1–34): two and a half years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res, in press.Google Scholar
  58. 57.
    Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH. 2000 Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1–34) therapy in women with severe osteoporosis. Bone 27:311–318.PubMedCrossRefGoogle Scholar
  59. 58.
    Melnick KA, Heathman M, O'Brien G, Gaich G, Satterwhite J. 2000 Evaluation of LY333334 [Recombinant human parathyroid hormone (1–34) treatment on total lumbar spine and femoral neck bone mineral density in postmenopausal osteoporotic women. AAPS Pharm Sci 2:abstract 586.Google Scholar
  60. 59.
    Miller PD, Hochberg MC, Wehren LE, Ross PD, Wasnich RD. 2005 How useful are measures of BMD and bone turnover? Curr Med Res Opin 21:545–553.PubMedCrossRefGoogle Scholar
  61. 60.
    Zanchetta JR, Bogado CE, Ferretti JL et al. 2003 Effects of teriparatide [recombinant human parathyroid hormone (1–34) on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539–543.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2006

Authors and Affiliations

  1. 1.Amgen IncSouth San Francisco
  2. 2.Stanford University School of MedicineStanford
  3. 3.Colorado Center for Bone ResearchLakewood
  4. 4.University of Colorado School of MedicineDenver

Personalised recommendations